Pavlos Papakotoulas Selected Research

Pavlos Papakotoulas Research Topics

Disease

13	Neoplasms (Cancer) 04/2022 - 01/2005
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 07/2004
4	Adenocarcinoma 04/2022 - 03/2012
4	Pancreatic Neoplasms (Pancreatic Cancer) 06/2021 - 02/2018
3	Neutropenia 08/2013 - 01/2005
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2010 - 03/2004
2	Sarcoma (Soft Tissue Sarcoma) 04/2022 - 08/2013
2	Thrombosis (Thrombus) 04/2022 - 01/2020
2	Hemorrhage 04/2022 - 01/2020
2	Lung Neoplasms (Lung Cancer) 12/2017 - 01/2010
2	Breast Neoplasms (Breast Cancer) 07/2017 - 01/2010
2	Exanthema (Rash) 08/2013 - 01/2013
2	Carcinoma (Carcinomatosis) 03/2012 - 01/2005
2	Ovarian Neoplasms (Ovarian Cancer) 01/2008 - 01/2005
1	Drug-Related Side Effects and Adverse Reactions 04/2022
1	Venous Thromboembolism 04/2022
1	Kidney Diseases (Kidney Disease) 04/2022
1	Obesity 04/2022
1	Stomach Neoplasms (Stomach Cancer) 03/2022
1	Wounds and Injuries (Trauma) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2020
1	Thrombocytopenia (Thrombopenia) 08/2013
1	Asthenia 08/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2012
1	Disease Progression 12/2006
1	Febrile Neutropenia 01/2005

Drug/Important Bio-Agent (IBA)

9	Gemcitabine FDA Link 06/2021 - 03/2004
6	Docetaxel (Taxotere)FDA Link 07/2017 - 03/2004
6	Cisplatin (Platino)FDA LinkGeneric 02/2012 - 07/2004
4	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 04/2022 - 01/2020
3	Tinzaparin (Innohep)FDA Link 04/2022 - 06/2021
3	Pharmaceutical PreparationsIBA 04/2022 - 01/2005
3	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2013
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2013 - 03/2012
2	130-nm albumin-bound paclitaxelIBA 06/2021 - 06/2021
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2013
2	Epirubicin (Ellence)FDA LinkGeneric 07/2017 - 01/2010
2	thiamine triphosphorate (TTP)IBA 08/2013 - 01/2010
2	PlatinumIBA 01/2010 - 01/2008
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2008 - 12/2006
1	TrabectedinIBA 04/2022
1	Platinum Compounds (Compounds, Platinum)IBA 04/2022
1	AnticoagulantsIBA 04/2022
1	trifluridine tipiracil drug combinationIBA 03/2022
1	AfatinibIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 02/2020
1	Bevacizumab (Avastin)FDA Link 01/2020
1	Nucleic AcidsIBA 01/2019
1	Ciclopirox (Loprox)FDA LinkGeneric 02/2018
1	Antifungal AgentsIBA 02/2018
1	DNA (Deoxyribonucleic Acid)IBA 12/2017
1	Formaldehyde (Formol)FDA Link 12/2017
1	RNA (Ribonucleic Acid)IBA 12/2017
1	ParaffinIBA 12/2017
1	Taxoids (Taxanes)IBA 07/2017
1	AnthracyclinesIBA 07/2017
1	Pemetrexed (MTA)FDA Link 08/2013
1	Gefitinib (Iressa)FDA Link 01/2013
1	Etoposide (VP 16)FDA LinkGeneric 07/2010
1	Topotecan (Hycamtin)FDA LinkGeneric 07/2010
1	Fluorouracil (Carac)FDA LinkGeneric 01/2010
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2010
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2010
1	Irinotecan (Camptosar)FDA LinkGeneric 08/2009
1	taxaneIBA 12/2006
1	Vinorelbine (Navelbine)FDA LinkGeneric 05/2006
1	liposomal doxorubicin (Doxil)FDA Link 01/2005
1	Carboplatin (JM8)FDA LinkGeneric 01/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2005

Therapy/Procedure

7	Therapeutics 04/2022 - 01/2013
6	Drug Therapy (Chemotherapy) 06/2021 - 01/2005
2	Adjuvant Chemotherapy 07/2017 - 01/2010
2	gemcitabine-oxaliplatin regimen 01/2008 - 12/2006
1	Catheters 04/2022
1	Immunotherapy 02/2020
1	CP protocol 01/2005